These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27288726)

  • 1. Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy.
    Jaffrès PA; Gajate C; Bouchet AM; Couthon-Gourvès H; Chantôme A; Potier-Cartereau M; Besson P; Bougnoux P; Mollinedo F; Vandier C
    Pharmacol Ther; 2016 Sep; 165():114-31. PubMed ID: 27288726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
    Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
    Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine.
    Gajate C; Mollinedo F
    Anticancer Agents Med Chem; 2014 May; 14(4):509-27. PubMed ID: 24628241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria.
    Mollinedo F; Fernández M; Hornillos V; Delgado J; Amat-Guerri F; Acuña AU; Nieto-Miguel T; Villa-Pulgarín JA; González-García C; Ceña V; Gajate C
    Cell Death Dis; 2011 May; 2(5):e158. PubMed ID: 21593790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid rafts as major platforms for signaling regulation in cancer.
    Mollinedo F; Gajate C
    Adv Biol Regul; 2015 Jan; 57():130-46. PubMed ID: 25465296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid rafts and Fas/CD95 signaling in cancer chemotherapy.
    Gajate C; Mollinedo F
    Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):274-83. PubMed ID: 21762074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.
    Gajate C; Mollinedo F
    Blood; 2007 Jan; 109(2):711-9. PubMed ID: 17003375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids.
    Castro BM; Fedorov A; Hornillos V; Delgado J; Acuña AU; Mollinedo F; Prieto M
    J Phys Chem B; 2013 Jul; 117(26):7929-40. PubMed ID: 23738749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasis.
    Girault A; Haelters JP; Potier-Cartereau M; Chantome A; Pinault M; Marionneau-Lambot S; Oullier T; Simon G; Couthon-Gourvès H; Jaffrès PA; Corbel B; Bougnoux P; Joulin V; Vandier C
    Curr Cancer Drug Targets; 2011 Nov; 11(9):1111-25. PubMed ID: 21999627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells.
    Gajate C; Gonzalez-Camacho F; Mollinedo F
    PLoS One; 2009; 4(4):e5044. PubMed ID: 19352436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells.
    Alves ACS; Dias RA; Kagami LP; das Neves GM; Torres FC; Eifler-Lima VL; Carvalho I; de Miranda Silva C; Kawano DF
    Curr Med Chem; 2018; 25(18):2082-2104. PubMed ID: 29332565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy.
    Mollinedo F; Gajate C
    Drug Resist Updat; 2006; 9(1-2):51-73. PubMed ID: 16687251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor.
    Mollinedo F; Gajate C; Martín-Santamaría S; Gago F
    Curr Med Chem; 2004 Dec; 11(24):3163-84. PubMed ID: 15579006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edelfosine in membrane environment - the Langmuir monolayer studies.
    Dynarowicz-Latka P; Hac-Wydro K
    Anticancer Agents Med Chem; 2014 May; 14(4):499-508. PubMed ID: 24628234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis.
    Gajate C; Del Canto-Jañez E; Acuña AU; Amat-Guerri F; Geijo E; Santos-Beneit AM; Veldman RJ; Mollinedo F
    J Exp Med; 2004 Aug; 200(3):353-65. PubMed ID: 15289504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane peroxidative damage enhancement by the ether lipid class of antineoplastic agents.
    Wagner BA; Buettner GR; Burns CP
    Cancer Res; 1992 Nov; 52(21):6045-51. PubMed ID: 1394229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of metastatic organ colonization and antiangiogenic activity of the orally bioavailable lipid raft-targeted alkylphospholipid edelfosine.
    Alonso-Pérez V; Hernández V; Calzado MA; Vicente-Blázquez A; Gajate C; Soler-Torronteras R; DeCicco-Skinner K; Sierra A; Mollinedo F
    Biomed Pharmacother; 2024 Feb; 171():116149. PubMed ID: 38266621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-O-octadecyl-2-O-methylglycero-3-phosphocholine (Edelfosine) and cancer cell invasion: a short review.
    Van Slambrouck S; Steelant WF
    Anticancer Agents Med Chem; 2014 May; 14(4):539-44. PubMed ID: 24628232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface-active properties of the antitumour ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (edelfosine).
    Busto JV; Sot J; Goñi FM; Mollinedo F; Alonso A
    Biochim Biophys Acta; 2007 Jul; 1768(7):1855-60. PubMed ID: 17543274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts.
    Van der Luit AH; Budde M; Zerp S; Caan W; Klarenbeek JB; Verheij M; Van Blitterswijk WJ
    Biochem J; 2007 Jan; 401(2):541-9. PubMed ID: 17049047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.